Harbor Capital Advisors Inc. Acquires New Shares in Merus (NASDAQ:MRUS)

Harbor Capital Advisors Inc. acquired a new position in Merus (NASDAQ:MRUS) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 42,287 shares of the biotechnology company’s stock, valued at approximately $2,113,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 489 shares during the period. California State Teachers Retirement System boosted its position in Merus by 2.9% during the 1st quarter. California State Teachers Retirement System now owns 33,745 shares of the biotechnology company’s stock valued at $1,520,000 after acquiring an additional 936 shares in the last quarter. Swiss National Bank boosted its position in Merus by 1.9% during the 1st quarter. Swiss National Bank now owns 74,054 shares of the biotechnology company’s stock valued at $3,335,000 after acquiring an additional 1,400 shares in the last quarter. nVerses Capital LLC increased its holdings in shares of Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,500 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Merus in the 1st quarter worth $72,000. 96.14% of the stock is currently owned by institutional investors.

Merus Stock Performance

Shares of MRUS stock opened at $51.23 on Tuesday. Merus has a fifty-two week low of $22.01 and a fifty-two week high of $61.61. The firm has a market capitalization of $3.49 billion, a PE ratio of -12.97 and a beta of 1.12. The stock’s 50-day simple moving average is $50.84 and its 200-day simple moving average is $51.44.

Analyst Upgrades and Downgrades

MRUS has been the topic of a number of recent research reports. Canaccord Genuity Group raised Merus to a “strong-buy” rating in a research report on Thursday, July 25th. Lifesci Capital raised shares of Merus to a “strong-buy” rating in a research report on Monday, July 29th. HC Wainwright reissued a “buy” rating and set a $85.00 target price on shares of Merus in a research report on Friday. Needham & Company LLC restated a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Friday. Finally, UBS Group began coverage on Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merus currently has a consensus rating of “Buy” and a consensus target price of $86.70.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.